The National Institutes of Health (NIH) intends to award a sole-source contract to Wilson Wolf Manufacturing LLC for seven cases of G-Rex500M-CS bioreactors. These bioreactors are required to support the manufacture of cell-based therapies for patients enrolled in NIH clinical trials at the NIH Clinical Center in Bethesda, MD. Wilson Wolf is the only known source for these validated bioreactors, as substituting another product would require extensive process validation and cause delays. The government will consider capability statements from interested parties, which must be submitted electronically by July 17, 2026, at 11:00 a.m. Eastern Time. No budget amount is specified in this notice.